The recall involves Lot# GMML24026A (NDC# 29300-415-19) with an expiration date of September 2027. Unichem Pharmaceuticals is recalling 1 lot of Cyclobenzaprine Hydrochloride Tablets USP, 10mg due to ...

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors. Apace ...

Cyclobenzaprine is a generic drug that’s prescribed for muscle spasms. As with other drugs, cyclobenzaprine can cause side effects, such as drowsiness and anxiety. Cyclobenzaprine oral tablets are not ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A sublingual tablet form of the muscle relaxant ...

Details concerning the Cyclobenzaprine combination medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, ...

Please provide your email address to receive an email when new articles are posted on . Tonmya significantly reduced daily pain vs. placebo in a phase 3 trial in fibromyalgia. Fast track designation ...

CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...

The FDA has approved cyclobenzaprine hydrochloride sublingual tablets (Tonmya, Tonix Pharmaceuticals), a first-in-class, nonopioid treatment for adults with fibromyalgia, a chronic pain syndrome that ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and ...